

Associate Christopher Ferenc Comments on IPR Proceedings in *BioPharm Insight*

March 27, 2014

Christopher Ferenc, an associate in the Intellectual Property practice, spoke with *BioPharm Insight* regarding *inter partes* review (IPR) proceedings, which employ a different set of standards than litigation since they lack the presumption of validity. Christopher notes that from the perspective of a patent challenger, IPR proceedings could therefore make patents easier to invalidate. (“Lilly Could Attempt Inter Partes Review Route to Hasten Insulin Glargine Approval in Legal Action Against Sanofi – Attorneys,” February 27, 2014)

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Christopher B. Ferenc

+1.202.625.3647

christopher.ferenc@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2025 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.